Beijing Tiantan Biological Products Co., Ltd. Stock price

Equities

600161

CNE000000WF9

Pharmaceuticals

End-of-day quote Shanghai S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
25.5 CNY -1.92% Intraday chart for Beijing Tiantan Biological Products Co., Ltd. -5.76% -17.58%
Sales 2023 * 5.24B 724M Sales 2024 * 6.2B 857M Capitalization 42.84B 5.93B
Net income 2023 * 1.12B 155M Net income 2024 * 1.38B 191M EV / Sales 2023 -
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 6.91 x
P/E ratio 2023 *
38.2 x
P/E ratio 2024 *
31 x
Employees 4,568
Yield 2023 *
0.6%
Yield 2024 *
0.4%
Free-Float 44.48%
More Fundamentals * Assessed data
Dynamic Chart
Tiantan Biological Products Scraps Clinical Trial of Intravenous Cytomegalovirus Human Immunoglobulin MT
Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China Baoli Technologies Chairman Redesignated as Vice Chairman MT
Didi Global Reports Q3 Revenue of RMB 51.4 Billion, Up 25% YoY RE
DIDI- ON NOV 11, YI ZHANG RESIGNED AS DIRECTOR OF THE CO, CHEN S… RE
Tiantan Biological Products Secures Another Blood Collection License MT
Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tiantan Biological Products' Profit Jumps 47.7% in First Three Quarters; Shares Up 5% MT
Tiantan Biological Products' Unit Gets Nod to Register Intravenous Human Immunoglobulin, Passes Regulatory Inspection MT
Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) added to S&P Global BMI Index CI
Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) added to FTSE All-World Index CI
Beijing Tiantan Biological Products Lands Blood Collection License in China’s Liping County MT
Tiantan Biological Unit Registers Blood Disorder Treatment; Shares Jump 4% MT
Tiantan Biological Products Secures Another Blood Plasma Collection License MT
Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news
1 day-0.57%
1 week-3.92%
Current month-8.13%
1 month-6.14%
3 months-15.56%
6 months+0.62%
Current year-15.97%
More quotes
1 week
25.85
Extreme 25.85
26.60
1 month
25.85
Extreme 25.85
28.60
Current year
24.20
Extreme 24.2
31.35
1 year
23.00
Extreme 23
32.73
3 years
14.93
Extreme 14.9333
38.58
5 years
13.43
Extreme 13.4259
44.58
10 years
5.68
Extreme 5.6809
44.58
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 17-04-24
Chairman 57 11-05-31
Investor Relations Contact - 06-02-28
Members of the board TitleAgeSince
Director/Board Member 56 20-06-22
Chairman 57 11-05-31
Director/Board Member 61 20-06-22
More insiders
Date Price Change Volume
24-03-27 25.5 -1.92% 12 528 180
24-03-27 26 -0.57% 7,019,324
24-03-26 26.15 +0.58% 6,821,902
24-03-25 26 -0.69% 7,498,190
24-03-22 26.18 -1.50% 8,940,636

End-of-day quote Shanghai S.E., March 26, 2024

More quotes
BEIJING TIANTAN BIOLOGICAL PRODUCTS CORPORATION LIMITED is a China-based company principally engaged in the biopharmaceutical businesses. The Company's primary products include preventive products, blood products and other biological products, such as the influenza A (H1N1) vaccines (split, inactivated),hepatitis B vaccines, poliomyelitis vaccines, measles-mump-rubella (MMR) vaccines, encephalitis B vaccines, influenza vaccinations, bacterial vaccines, human serum albumin (HSA) and intravenous immunoglobulin (IVIG), among others. The Company mainly distributes its products within domestic markets and to Hong Kong markets.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
26 CNY
Average target price
31.48 CNY
Spread / Average Target
+21.06%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Beijing Tiantan Biological Products Co., Ltd. - Shanghai S.E.